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Summary
The issue of human lifespan has long been a matter of controversy among scientists. In spite of
the recent claim by Dong et al that human lifespan is limited to 115 years, with the mounting
improvements in biotechnology and scientific understanding of aging, we may be confident that
aging will slow down over the course of the current century extending human longevity much
longer than 115 years.
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n a paper entitled “Evidence for a limit to human
lifespan” by Dong et al that was published in Nature
Vol. 538 (October 13, 2016),1 the authors concluded
that human lifespan is limited to 115 years and the
probability of a lifetime exceeding 125 in any given year
is less than 1 in 10 000. After about 8 months, the topic
is now up for debate again. Five brief communications
from different research groups have appeared in Nature
Vol. 546 (June 29, 2017),2-6 all disagreeing with the paper’s

conclusion that the human lifespan is limited to 115
years. The critics have analyzed the paper from different
viewpoints. The arguments focus primarily on different
aspects of the statistical analysis, the limited availability
of data, the splitting of the study period into two ranges
(1968–1994 and 1995–2006), the failure to collect and
verify the lifespan of extremely long-lived individuals, and
the disregard for possible other trajectories. However, the
authors of the paper have rejected all of these critics in
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different rebuttal letters (Nature Vol. 546) and defended
their conclusion of a human lifespan limited to 115 years.
The issue of human lifespan has long been a matter of
controversy among scientists. According to Olshansky and
Carnes,7 there are three opposing viewpoints on human
longevity, those of “Futurists,” “Optimists,” and “Realists.”
Futurists believe in the continuous extension of
human life with no limitation. They rely on forthcoming
improvements in different biotechnological domains that
will dramatically transform the landscape of human aging
and longevity toward a physical immortality and eternal
youth.
Optimists believe that the existing increase in life
expectancy, which began during the last century, will
continue its linear increase at about 2.5 years per decade.
Optimists, too, rely on biomedical technologies not
currently available and do not foresee any limit to a
continuous increase in life expectancy.
Realists, however, argue that human lifespan is
biologically determined and that continuous increase in
life expectancy is, practically, implausible. They believe
that there are many factors interfering with the duration of
human life, as well as with the lifespans of other organisms.
Aging, itself, is a fact that, according to existing scientific
knowledge, cannot be stopped or reversed. It may be
slowed down, but it is unlikely to have a perceptible
impact on life expectancy. Therefore, Realists believe in
the existence of a life boundary that is like a warranty
period or expiration date, limiting lifespan and, hence,
longevity.7
There is no doubt that, due to scientific advances in
biotechnology and medicine, human life expectancy
has increased during the last century. According to
the National Institute on Aging, while the average life
expectancy for babies born in 1900 was only 47 years, it rose
to 79 years in 1998. Meanwhile, the title for the longest life
recorded in human history belongs to the French woman
Jeanne Calment, who lived 122 years (1875-1997).8 It is
also notable that the upward course in life expectancy
has slowed down during the current century. While the
precise limit to human longevity is arguable, based on the
current state of our medical and biomedical knowledge,
some limit or range of limit is necessary. Therefore, human
immortality and eternal life, as supported by Futurists,
appears to be out of the question. Clearly, the study done
by Dong et al.1 suffers from restricted sample availability.
A more realistic evaluation of human longevity requires
not only a longer study duration, which would, in turn,
provide an increased sample size but also a carefully
designed study plan and data analyzing strategy.
The increase in life expectancy during the last century
was mostly due to improvements in public health and
achievements in declining early age mortalities. In the
future, the escalation in human lifespan will depend
on healthier lifestyles and the availability of improved
biomedical advances and biotechnologies. With scientific
interventions and environmental improvements, we may
be confident that aging will slow down over the course of
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the current century.
Aging may be inevitable, but the rate of aging may not
be so if we recognize the causes of aging. What appears
to play a more influential role in limiting lifespan is the
progressive accumulation of molecular damage inside the
cells. While any kind of structural and molecular damage
may profoundly affect cell function and accelerate the
aging process, damage to DNA structure, because of
its vital role in life, has been a focal point, giving rise to
the “DNA damage theory of aging.” Both mitochondrial
and nuclear DNA damage lead to the development
of pathological conditions that accelerate aging and
senescence. Fortunately, our cells are equipped with
mechanisms that can efficiently repair these damages.
However, over time, some of these repair mechanisms may
fail or their function may be blocked by other molecules.
Therefore, damaged DNA will remain unrepaired and, as
time goes on, accumulate, disturbing cell function and
affecting lifespan.
One of the DNA repair pathways relies on the
restoration activity of “poly-adenosine diphosphate–
ribose-polymerase 1” (PARP1). The repair function of
this enzyme can be inhibited by another protein called
“deleted in breast cancer 1” (DBC1). The DBC1 gene was
originally found to be deleted in some breast cancer cells.9
This protein seems to be involved in the regulation of
cancer cell energy metabolism.10 A recent study by Li et
al11 has revealed that both PARP1 and the oxidized form
of “nicotinamide adenine dinucleotide” (NAD+) compete
with each other in binding to the DBC1 protein, therefore,
keeping PARP1 unblocked and capable of DNA repair.
Experiments conducted in old mice,11 have shown
that age-related DNA damage diminishes when the
cellular level of NAD+ is increased. The outcome of
these experiments suggests that as NAD+ levels decline
with age, fewer NAD+ molecules are available to prevent
DBC1 binding PARP1. Therefore, unblocked DBC1 will
bind PARP1 and damaged DNA will remain unrepaired.
The accumulation of the unrepaired DNA, over time,
will gradually paralyze cell function. In an increased
abundance of NAD+, the harmful action of DBC1 will
be stopped and DNA repair with PARP1 will continue
slowing down the aging process.
Another study just published in Nature (July 26, 2017)12
demonstrates the role of renewed neuro-stem cells
(NSCs) in the hypothalamic region of the mouse brain.
While the pivotal role of the hypothalamus in whole body
aging was shown previously,13 in this study the authors
demonstrated that besides the known neurogenesis role of
the hypothalamic NSCs, these cells contribute greatly in
the production of exosomal microRNAs (miRNAs) in the
cerebrospinal fluid. These exosomes, which are linked to
the neuro-stem cell function, and therefore, to whole body
aging, can be produced from the cultured hypothalamic
NSCs and delivered to the brain hypothalamic area. While
the exosomal miRNAs production declines during aging,
their increased level in the treated mice leads to slow down
the aging process.12

Human aging and lifespan

Given the crucial biological differences between mice
and humans, the applicability of these treatments in
humans and their positive results remain to be seen. In the
best case of scenario, expecting an increase in average life
expectancy for young generations of about 100 years and
longevity over 125 years appears to be reasonable.
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